Elanco Animal Health reported QQ1 2025 revenue of $1.193 billion, down 1% year-over-year and up approximately 17% quarter-over-quarter, signaling a modest top-line contraction versus the prior year with a meaningful sequential rebound. Gross profit stood at $556 million for a gross margin of about 46.6%, while operating income was $121 million (approximately 10.1% operating margin). Net income of $67 million yielded a 5.6% net margin and earnings per share (EPS) of $0.14 (diluted $0.13). The quarter featured a negative free cash flow (FCF) of $69 million, driven by negative working capital dynamics and capital expenditure of $65 million, resulting in a net cash used in operating activities of $4 million. Balance sheet leverage remains elevated, with total debt of $4.395 billion and net debt of $3.908 billion against cash of $487 million, producing a conservative cash/EBITDA posture. With goodwill and intangible assets totaling roughly $8.14 billion against equity of $6.35 billion, the business is highly intangible-intensive, which informs impairment risk sensitivity and equity-beta dynamics. Valuation remains elevated versus many peers (P/E around 33x, EV/Revenue near 45x in the period), signaling a premium for growth expectations but highlighting the need for deleveraging and cash flow acceleration to sustain multiple expansion. Management commentary is not captured in the provided transcript data, limiting the ability to quote specific guidance or qualitative catalysts from the QQ1 call. The company’s exposure to a broad animal health market, including companion animal and food animal portfolios, continues to position it within a large addressable market, albeit with execution and balance sheet discipline as critical near-term catalysts.